Ingredient or product comparison
Peptides for Eye Health Protocol Evidence Guide: Comparison
Thymalin Immune modulation reducing retinal inflammation Animal models only; no human ophthalmic trials Subcutaneous injection (research) Preclinical Cerebrolysin Neurotrophic factor support for optic nerve One pilot study (n=18) showing 12% PERG improvement I
This source-based comparison does not add ratings or recommend a winner.
- Thymalin
- Immune modulation reducing retinal inflammation
- Animal models only; no human ophthalmic trials
- Subcutaneous injection (research)
- Preclinical
- Cerebrolysin
- Neurotrophic factor support for optic nerve
- One pilot study (n=18) showing 12% PERG improvement
- IV infusion (10-day protocol)
- Phase I equivalent
- Dihexa
- HGF receptor activation in retinal tissue
- Case series (n=5) with mixed visual acuity outcomes
- Sublingual (off-label, uncontrolled)
- Anecdotal
- P21 (CNTF derivative)
- Photoreceptor survival signaling
- Phase I safety trial (n=22) completed; Phase II ongoing
- Intravitreal injection
- Phase I complete
- Cartalax
- Cellular senescence reduction (theoretical ocular benefit)
- No ophthalmic trials; general aging studies only
- Oral or subcutaneous (research)
- Hypothesis stage